ScholarWorks Community:https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3402024-03-28T15:56:31Z2024-03-28T15:56:31ZDifferential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group's Comparative Survey StudyCho, Won KyungYoo, Gyu SangRim, Chai HongJeong, Jae-UkChie, Eui KyuAhn, Yong ChanCho, Hyeon-MinUm, Jun WonSuh, Yang-GunChang, Ah RamLee, Jong Hoonhttps://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/643682023-12-15T06:15:50Z2023-10-01T00:00:00ZTitle: Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group's Comparative Survey Study
Authors: Cho, Won Kyung; Yoo, Gyu Sang; Rim, Chai Hong; Jeong, Jae-Uk; Chie, Eui Kyu; Ahn, Yong Chan; Cho, Hyeon-Min; Um, Jun Won; Suh, Yang-Gun; Chang, Ah Ram; Lee, Jong Hoon
Abstract: Purpose Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary. Materials and Methods A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties. Results The radiation oncologists chose "bone" more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored "peritoneal seeding" (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that "irrelevant, if all metastatic lesions are amendable to local therapy", while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed. Conclusion This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.2023-10-01T00:00:00ZBarriers in Oligometastasis Care in Korea: Radiation Oncologists' PerspectivesChie, Eui KyuRim, Chai HongCho, Won KyungAhn, Yong Chanhttps://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/643662023-12-15T06:15:50Z2023-10-01T00:00:00ZTitle: Barriers in Oligometastasis Care in Korea: Radiation Oncologists' Perspectives
Authors: Chie, Eui Kyu; Rim, Chai Hong; Cho, Won Kyung; Ahn, Yong Chan2023-10-01T00:00:00ZRisk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary diseaseKim, HakyoungHwang, JeongeunKim, Sun MyungChoi, JuwhanYang, Dae Sikhttps://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/643532023-12-27T01:00:20Z2023-10-01T00:00:00ZTitle: Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease
Authors: Kim, Hakyoung; Hwang, Jeongeun; Kim, Sun Myung; Choi, Juwhan; Yang, Dae Sik
Abstract: Background We aim to identify the multifaceted risk factors that can affect the development of severe radiation pneumonitis (RP) in patients with non-small cell lung cancer (NSCLC) treated with curative high-dose radiotherapy with or without concurrent chemotherapy.Methods We retrospectively reviewed the medical records of 175 patients with stage-I-III NSCLC treated with curative thoracic X-ray radiotherapy at the Korea University Guro Hospital between June 2019 and June 2022. Treatment-related complications were evaluated using the Common Terminology Criteria for Adverse Events (version 4.03).Results The median follow-up duration was 15 months (range: 3-47 months). Idiopathic pulmonary fibrosis (IPF) as an underlying lung disease (P < 0.001) and clinical stage, regarded as the concurrent use of chemotherapy (P = 0.009), were associated with a high rate of severe RP. In multivariate analyses adjusting confounding variables, the presence of IPF as an underlying disease was significantly associated with severe RP (odds ratio [95% confidence interval] = 48.4 [9.09-347]; P < 0.001). In a subgroup analysis of stage-I-II NSCLC, the incidence of severe RP in the control, chronic obstructive pulmonary disease (COPD), and IPF groups was 3.2%, 4.3%, and 42.9%, respectively (P < 0.001). The incidence of severe RP was 15.2%, 10.7%, and 75.0% in the control, COPD, and IPF groups, respectively (P < 0.001) in the stage-III NSCLC group.Conclusions This study revealed that IPF as an underlying lung disease and the concurrent use of chemotherapy are associated with a high rate of severe RP. In contrast, COPD did not increase the risk of pulmonary toxicity after receiving curative high-dose radiotherapy.2023-10-01T00:00:00ZKorean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KRPark, Cheol-KyuOh, Hyung-JooKim, Young-ChulKim, Yong-HyubAhn, Sung-JaJeong, Won GiLee, Jeong YeopLee, Jae CheolChoi, Chang MinJi, WonjunSong, Si YeolChoi, JuwhanLee, Sung YongKim, HakyoungLee, Shin YupPark, JongmooYoon, Seong HoonJoo, Ji HyeonOh, In-Jaehttps://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/639732023-12-27T01:00:32Z2023-08-01T00:00:00ZTitle: Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Authors: Park, Cheol-Kyu; Oh, Hyung-Joo; Kim, Young-Chul; Kim, Yong-Hyub; Ahn, Sung-Ja; Jeong, Won Gi; Lee, Jeong Yeop; Lee, Jae Cheol; Choi, Chang Min; Ji, Wonjun; Song, Si Yeol; Choi, Juwhan; Lee, Sung Yong; Kim, Hakyoung; Lee, Shin Yup; Park, Jongmoo; Yoon, Seong Hoon; Joo, Ji Hyeon; Oh, In-Jae
Abstract: Introduction: This study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolida-tion (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC.Methods: Patients with stage III NSCLC who started DC after CRT between September 2018 and December 2020 and were treated at five tertiary hospitals in the Republic of Korea were included. The primary end point was real-world progression-free survival (rwPFS). Secondary end points were overall survival, objective response rate, and adverse events including radiation pneumonitis (RP) and immune-related adverse events (irAEs).Results: A total of 157 patients were enrolled. At the me-dian follow-up of 19.1 months, median rwPFS of DC was 25.9 months (95% confidence interval: 16.5-35.4) and the 1-, 2-, and 3-year rwPFS rates were 59.4%, 51.8%, and 43.5%, respectively. The median overall survival was not mature, and objective response rate of DC was 51.0%. High programmed death-ligand 1 expression (>50%) and development of RP requiring steroid treatment were significantly associated with longer (p = 0.043) and shorter rwPFS (p = 0.036), respectively. RP, RP requiring steroid treatment, and irAEs developed in 57 (36.3%), 42 (26.8%), and 53 (33.8%) patients, respectively. Among peripheral blood cell counts at the initiation of DC, a high derived monocyte-to-lymphocyte ratio was the most significant risk factor for the development of RP requiring steroid treatment (OR 44.76, 95% CI: 8.89-225.43, p < 0.001) and irAEs (OR 2.85, 95% CI: 1.27-6.41, p = 0.011).Conclusions: Compared with the outcome of the PACIFIC trial, these real-world data revealed favorable survival benefits of DC after CRT in patients with unresectable stage III NSCLC. Blood-based biomarkers could predict higher grade RP and irAEs before the initiation of DC.& COPY; 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).2023-08-01T00:00:00Z